HER2-positive breast cancer carries more HER2 protein on the tumor surface than normal cells. That protein acts like a stuck accelerator pedal, making the cancer spread faster than most hormone ...

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission. Tukysa ...

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC ...

Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer — Response rates reached 41-47% with different approaches in rare disease by Ian Ingram , Managing Editor, MedPage Today June 3 ...

OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial. The therapy, dubbed OST-HER2, uses a HER2 ...

An investigational antibody-drug conjugate proved active and safe for patients with previously treated HER2-mutant non-small cell lung cancer (NSCLC), a phase II trial from China showed.

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

HER2 is a protein that can cause a more aggressive form of breast cancer. ... This includes drugs that specifically work to kill or stop the growth of cancer-causing cells without damaging healthy ...

That’s because there are now drugs that target HER2, but these work only for cancers that are HER2+. A common drug for HER2+ breast cancer is trastuzumab ( Herceptin ), but there are others.

The treatment combines a new drug, inavolisib (Itovebi ®), with two older breast cancer drugs, fulvestrant (Faslodex ®) and palbociclib (Ibrance ®). Inavolisib, which targets PIK3CA mutations, appears ...